Developing next-generation in-vitro phenotypic assays for Huntington’s disease

This application note from bit.bio details how combining wild-type ioGlutamatergic Neurons™ and their isogenic disease model with MaxTwo high-density microelectrode arrays enables label-free, long-term characterization of disease phenotypes.The disease model showed delayed neuronal network formation compared to the wild-type control, and significant differences were found in single cells and axons. This approach offers physiologically relevant insights into human iPSC-derived Huntington’s disease modeling, making it a promising platform for high-content screening in drug discovery for Huntington’s disease.